Cubist Systematic Strategies LLC Makes New $1.06 Million Investment in Neuronetics, Inc. $STIM

Key Points

• Cubist Systematic Strategies LLC acquired a new position in Neuronetics, purchasing 286,571 shares valued at approximately $1,055,000, making up about 0.44% of the company's stock.
• Canaccord Genuity Group has lowered its price target for Neuronetics from $8.00 to $7.00, while analysts maintain a consensus rating of "Buy".
• Neuronetics reported a quarterly earnings loss of ($0.15) per share, missing estimates, despite revenue of $38.11 million surpassed expectations.

Cubist Systematic Strategies LLC acquired a new stake in Neuronetics, Inc. (NASDAQ:STIM - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 286,571 shares of the company's stock, valued at approximately $1,055,000. Cubist Systematic Strategies LLC owned 0.44% of Neuronetics at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Larson Financial Group LLC bought a new stake in shares of Neuronetics in the 1st quarter valued at approximately $25,000. KPP Advisory Services LLC bought a new stake in shares of Neuronetics in the 1st quarter valued at approximately $37,000. National Bank of Canada FI grew its stake in shares of Neuronetics by 19,491.5% in the 1st quarter. National Bank of Canada FI now owns 11,559 shares of the company's stock valued at $42,000 after purchasing an additional 11,500 shares during the period. FORA Capital LLC bought a new stake in shares of Neuronetics in the 1st quarter valued at approximately $42,000. Finally, Presidio Capital Management LLC bought a new stake in shares of Neuronetics in the 1st quarter valued at approximately $44,000. 53.59% of the stock is currently owned by institutional investors.

Neuronetics Trading Down 9.5%

NASDAQ:STIM traded down $0.33 during trading hours on Friday, hitting $3.13. 1,099,679 shares of the stock were exchanged, compared to its average volume of 1,477,073. The company has a market capitalization of $206.97 million, a P/E ratio of -2.77 and a beta of 1.28. The company has a quick ratio of 1.84, a current ratio of 2.02 and a debt-to-equity ratio of 1.76. The company's 50 day moving average is $3.74 and its two-hundred day moving average is $3.95. Neuronetics, Inc. has a twelve month low of $0.52 and a twelve month high of $5.92.

Neuronetics (NASDAQ:STIM - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.07). Neuronetics had a negative return on equity of 156.36% and a negative net margin of 43.47%.The firm had revenue of $38.11 million for the quarter, compared to the consensus estimate of $36.80 million. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, sell-side analysts anticipate that Neuronetics, Inc. will post -1.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reduced their target price on Neuronetics from $8.00 to $7.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Neuronetics presently has an average rating of "Buy" and an average price target of $7.00.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.